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Summary. Background: Agonist-induced platelet activation
involves different signaling pathways leading to the activation
of phospholipase C (PLC) b or PLCc2. Activated PLC
produces inositol 1,4,5-trisphosphate and diacylglycerol, which
trigger Ca2+ mobilization and the activation of protein
kinase C, respectively. PLCb is activated downstream of Gq-
coupled receptors for soluble agonists with only short interac-
tion times in flowing blood. In contrast, PLCc2 becomes
activated downstream of receptors that interact with immobi-
lized ligands such as the collagen receptor glycoprotein (GP) VI
or activated integrins. Objective and methods: We speculated
that PLCc2 activity might be optimized for sustained but
submaximal signaling to control relatively slow platelet
responses. To test this hypothesis, we analyzed platelets from
mice heterozygous for a gain-of-function mutation in the Plcg2
gene (Plcg2Ali5/+). Results: Plcg2Ali5/+ platelets showed en-
hanced Ca2+ mobilization, integrin activation, granule secre-
tion and phosphatidylserine exposure upon GPVI or C-type
lectin-like receptor-2 stimulation. Furthermore, integrin aIIbb3
outside-in signaling was markedly enhanced in the mutant
platelets, as shown by accelerated spreading on different
matrices and faster clot retraction. These defects translated into
virtually unlimited thrombus formation on collagen under
flow in vitro and a prothrombotic phenotype in vivo. Conclu-
sions: These results demonstrate that the enzymatic activity of
PLCc2 is tightly regulated to ensure efficient but limited platelet
activation at sites of vascular injury.
Keywords: integrin, platelet, PLCc2, signaling, thrombosis.
Introduction
Platelets are small anuclear cells that play a fundamental role in
hemostasis. They adhere to the injured vessel wall and recruit
other platelets to form a hemostatic plug that is critical in
limiting blood loss and initiating vascular repair. On the other
hand, platelet–platelet interactions can lead to inordinate
thrombus growth, which is a major pathomechanism in the
development of acute ischemic disorders, including stroke and
myocardial infarction [1].
At sites of injury, platelets are recruited to the exposed
extracellular matrix by the interaction of glycoprotein (GP)Ib–
V–IX with immobilized von Willebrand factor (VWF). This
interaction is characterized by a high dissociation rate, resulting
in platelet translocation. For stable adhesion to occur, intra-
cellular signals are required that lead to conformational
changes within integrin adhesion receptors, most notably
integrin aIIbb3, to allow efficient ligand binding. A recent study
has suggested that platelet aggregate formation is drivenmainly
by shear forces, most likely through a GPIb-triggered process
[2].Under flow, GPIb–VWF interactions can elicit intracellular
signals and weak aIIbb3 activation [3,4]. Full platelet activation,
however, requires the concerted action of strong platelet
agonists, such as collagens, thromboxane A2 (TxA2) and ADP
released from activated platelets as well as locally produced
thrombin [5]. These stimuli trigger different pathways leading
to the activation of phospholipase C (PLC), which comprises a
family of enzymes known to be important for platelet
activation and integrin regulation. Activated PLC produces
the intracellular messengers diacylglycerol (DAG) and inositol
1,4,5-trisphosphate (IP3). DAG activates protein kinase C
(PKC), and IP3 triggers Ca
2+ release from the endoplasmic
reticulum (ER)/sarcoplasmic reticulum (SR), followed by
sustained Ca2+ influx through the plasma membrane. This
so-called store-operated calcium entry is regulated by the ER/
SR-resident Ca2+ sensor stromal interaction molecule 1
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(Stim1) [6], and occurs through the four transmembrane
channel protein Orai1 [6,7]. Ca2+ mobilization and PKC
activation trigger vital platelet responses such as integrin
activation and degranulation [8].
Two major PLC isoforms are expressed in platelets, and
they become activated by different signaling pathways. PLCb
becomes activated downstream of G-protein (Gq)-coupled
receptors, which are mainly triggered by soluble agonists such
as ADP and TxA2 or locally produced thrombin with only
short interaction times in flowing blood [9,10]. In contrast,
PLCc2 is activated by signaling pathways involving tyrosine
phosphorylation cascades downstream of receptors that
predominantly interact with immobilized ligands and may
trigger sustained signaling events. The best characterized
PLCc2-activating receptors in platelets are the immunorecep-
tor tyrosine-based activation motif (ITAM)-coupled collagen
receptor GPVI, FccRIIa, ligand-occupied integrins, and
possibly also GPIb. In addition, the recently identified C-
type lectin-like receptor-2 (CLEC-2) also strongly activates
PLCc2 in platelets, and mediates powerful cellular activation.
CLEC-2 was identified as the receptor for the snake venom
toxin rhodocytin [11], and appears to be involved in the
stabilization of newly formed thrombi under flow [12]. The
physiologic ligand that stimulates CLEC-2 under these
conditions has not been identified, but it is hypothesized to
be expressed or immobilized on the surfaces of activated
platelets [12]. These observations raise the interesting hypoth-
esis that PLCb is optimized for fast and maximal activity,
whereas PLCc2 may be designed to mediate sustained,
adhesion-dependent signaling events that require prolonged
rather than transient PLC activity. To characterize the
function of PLCc2 activity in platelets, a genetically domi-
nant gain-of-function murine model, designated Ali5 [13],
was employed. Plcg2Ali5/+ mice develop severe autoimmune
and autoinflammatory symptoms reminiscent of human
systemic lupus erythematosus. Biochemical analysis suggests
that the mutation D993G in PLCc2 affects a conserved
residue in the catalytic domain of the enzyme, which could
compromise autoinhibition in the inactive PLC, facilitating
the activation process. In addition, the removal of the
negative charge may enhance membrane interaction in the
activated state without compromising substrate binding and
hydrolysis [14].
In the current study, we show that platelets from Plcg2Ali5/+
mice display enhanced outside-in signaling of aIIbb3 and
markedly enhanced thrombus formation and stability upon
GPVI/CLEC-2 stimulation in vitro, which translates into a
prothrombotic phenotype in vivo.
Materials and methods
Animals
N-ethyl-N-nitrosourea mutagenesis of C3HeB/FeJ male mice
was performed as previously described [13]. C3H Ali5-affected
female mice were mated with C3H wild-type males, and the
heterozygous offspring were used for analysis. Wild-type
C3HeB/FeJ mice were used as controls.
Reagents
ADP and high molecular weight heparin were purchased from
Sigma (Deisenhofen, Germany), a-thrombin was purchased
from Roche Diagnostics (Mannheim, Germany), and apyrase
type III was purchased from Sigma-Aldrich (Taufkirchen,
Germany). Indomethacin was purchased via a local pharmacy.
Collagen-related peptide (CRP) was generated as described
previously [15]. The antibody against the activated form of
aIIbb3 (JON/A–phycoerythrin) was from Emfret Analytics
(Würzburg, Germany). All other antibodies were generated
and modified in our laboratory as previously described [16].
Rhodocytin was isolated as previously described [17].
Platelet preparation
Mice were bled from the retro-orbital plexus under ether
anesthesia. Blood was collected in a tube containing
20 U mL)1 heparin, and platelet-rich plasma (PRP) was
obtained by centrifugation at 300 · g for 10 min at room
temperature. For the preparation of washed platelets, PRPwas
washed twice at 1000 · g for 8 min at room temperature, and
the pellet was resuspended in modified Tyrodes buffer
[134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM
NaHCO3, 5 mM HEPES, 5 mM glucose, 0.35% bovine serum
albumin (BSA), pH 7.4] in the presence of prostacyclin
(0.1 lg mL)1) and apyrase (0.02 U mL)1). Platelets were
finally resuspended in the same buffer without prostacyclin
(pH 7.4, 0.02 U mL)1 apyrase) and incubated at 37 C for
30 min before use.
Aggregometry
To determine platelet aggregation, light transmission was
measured using PRP or washed platelets. Transmission was
recorded on a Fibrintimer four-channel aggregometer
(APACT Laborgeräte und Analysensysteme, Hamburg, Ger-
many) over 10 min, and was expressed as arbitrary units, with
100% transmission adjusted with plasma. Platelet aggregation
was induced by addition of CRP, collagen, U46619 or ADP at
the indicated concentrations. Thrombin-induced aggregation
was performed with washed platelets [200 lL with
0.5 · 106 platelets lL–1 in Tyrodes buffer (pH 7.4) + 2 mM
CaCl2].
Flow cytometry
Fifty microliters of blood was collected, washed twice in
phosphate-buffered saline (PBS), and diluted 1 : 20 in Tyrodes
buffer (pH 7.4). Samples were activated with agonists at the
indicated concentrations, and stained with fluorophore-conju-
gated monoclonal antibodies at saturating concentrations for
10 min at 37 C. Samples were analyzed directly on a
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FACSCalibur (BD Biosciences, Heidelberg, Germany). Plate-
lets were identified by forward scatter/side scatter characteris-
tics.
Adhesion under flow conditions
Rectangular coverslips (24 · 60 mm) were coated with
0.2 mg mL)1 fibrillar type I collagen (Nycomed, Singen,
Germany) for 1 h at 37 C and blocked with 1% BSA.
Heparinized whole blood was labeled with a DyLight 488-
conjugated anti-GPIX Ig derivative at 0.2 lg mL)1, and
perfusion was performed as previously described [18]. Image
analysis was performed off-line using METAVUE software
(Visitron, Puchheim, Germany). Thrombus formation was
expressed as the mean percentage of total area covered by
thrombi, and as the mean integrated fluorescence intensity per
square millimeter.
Intracellular Ca2+ measurements
Platelet intracellular free Ca2+ measurements were per-
formed as previously described [19]. Briefly, platelets isolated
from blood were washed, suspended in Tyrodes buffer
without Ca2+, and loaded with Fura-2/AM (5 lM) in the
presence of Pluronic F-127 (0.2 lg mL)1) (Molecular Probes,
Karlsruhe, Germany) for 30 min at 37 C. After labeling,
platelets were washed once and resuspended in Tyrodes
buffer containing either no Ca2+ or 1 mM CaCl2. Stirred
platelets were activated with agonists, and fluorescence was
measured with a PerkinElmer LS 55 fluorimeter. Excitation
was alternated between 340 nm and 380 nm, and emission
was measured at 509 nm. Each measurement was calibrated
using Triton X-100 and EGTA.
Measurement of inositol 1-phosphate (IP1)
The IP-One enzyme-linked immunosorbent assay (ELISA) kit
was from Cisbio (Bagnols-sur-Cèze, France). Washed murine
platelets were adjusted to a concentration of 0.7 · 106 lL)1 in
modifiedphosphate-freeTyrodesbuffercontaining2 mMCaCl2
and50 mMLiCl.Apyrase, indomethacinandEDTAwereadded
to final concentrations of 2 U mL)1, 10 lM, and 5 mM, respec-
tively. Platelets were activated with the indicated agonists for
5 min at 37 C (350 · g). After stimulation, platelets were lysed
inthebuffersuppliedbythekit.Fiftymicrolitersof lysedplatelets
was used for the IP1 ELISA assay, according to the manufac-
turers protocol.
Measurement of ATP release
Washed platelets were adjusted to a concentration of
0.4 · 106 lL)1. Platelets were activated with the indicated
agonists for 2 min at 37 C with stirring (1000 · g). Following
activation, EDTA (3 mM final concentration) and formalde-
hyde (0.1% final concentration) were added, and platelets were
fixed for 2 h. The platelets were then centrifuged for 1 min at
16 000 · g, and 100 lL of supernatant was added to 100 lL of
absolute ethanol. Samples were stored at ) 20 C until
measurement. The levels of ATP in 12.5-lL samples were
quantified using a bioluminescence assay kit (Roche Diagnos-
tics, Mannheim, Germany) and a Fluostar Optima luminom-
eter (BMG Lab Technologies, Offenburg, Germany).
Clot retraction assay of murine platelets
Clot retraction studies were performed at 37 C in an
aggregometer tube containing diluted PRP (500 lL,
3 · 108 mL)1 platelets), thrombin (5 U mL)1), and CaCl2
(20 mM). Clot retraction was recorded with a digital camera
and by measurement of the removable volume of clear fluid at
the end of the experiment.
Spreading experiments
Coverslips were coated overnight with 1 mg mL)1 human
fibrinogen, 200 lg mL)1 soluble type I collagen, or
50 lg mL)1 laminin, respectively, and then blocked for 1 h
with 1%BSA in PBS. Washed platelets of mutant or wild-type
mice were resuspended at a concentration of 0.5 · 106 plate-
lets lL)1, and then further diluted 1 : 10 in Tyrodes buffer.
Platelets were seeded on the respective coverslips and incubated
at room temperature for the indicated times. Platelets allowed
to spread on fibrinogen were activated with 0.008 U mL)1
thrombin shortly before seeding. Unbound platelets were
removed by rinsing with Tyrodes buffer. Adherent platelets
were fixed with 4% paraformaldehyde and analyzed by
differential interference contrast microscopy. At least 10 images
of each sample were taken and analyzed using METAVUE
software (Visitron).
Pulmonary thromboembolism model
Mice were anesthetized by intraperitoneal injection of trib-
romoethanol (Avertin), at 0.15 mL per 10 g body weight, from
a 2.5% solution. Anesthetized mice received a mixture of
collagen (0.15 mg kg)1) and epinephrine (60 lg kg)1) injected
in the jugular vein. The surviving mice were allowed to recover.
Determination of phosphatidylserine (PS)-exposing platelets
after perfusion
Adhesion experiments under flow conditions (1000 s)1) were
performed with heparanized whole blood containing PPACK
(30 lM) [18]. Rectangular coverslips were coated with type I
collagen (Nycomed), rinsed with saline, and blocked with 1%
BSA. To prevent coagulation, the chamber and tubing were
prewashed with Tyrodes buffer supplemented with 1 U mL)1
heparin. The blood was perfused through the flow chamber by
using a 1-mL syringe and a pulse-free pump at a shear rate of
1000 s)1 for 4 min. The flow chamber was rinsed with Tyrodes
buffer supplemented with 1 U mL)1 heparin and 2 mM CaCl2
at the same shear rate for another 4 min. Exposure of PS was
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detected with OG488-labeled annexin A5 (1 lg mL)1). Phase-
contrast and fluorescent images were obtained from at least
seven different collagen-containing microscopic fields, which
were randomly chosen.
Data analysis
Results are shown as means ± standard deviations from at
least three individual experiments per group. Differences
between wild-type and Plcg2Ali5/+ mice were assessed by the
Mann–WhitneyU-test. P-values < 0.05 were considered to be
statistically significant.
Results
The significance of PLCc2 for platelet activation was analyzed
by comparing wild-type mice with mice heterozygous for a
point mutation in the Plcg2 gene that leads to a single amino
acid substitution in the catalytic domain of the enzyme that
results in a gain-of-function mutation (Plcg2Ali5/+). This point
mutation did not lead to increased tyrosine phosphorylation of
the enzyme in response to GPVI stimulation, as shown by
whole cell tyrosine phosphorylation experiments. Interestingly,
a tendency for slightly faster dephosphorylation of bands
comigrating with PLCc2 and FcR c-chain at 150 kDa and
14 kDa, respectively, was observed in mutant platelets at the
latest time point (120 s; Fig. S1A). However, immunoprecip-
itation experiments confirmed comparable increases in tyrosine
phosphorylation of PLCc2 in control and mutant platelets up
to 90 s after stimulation (Fig. S1B). C3H-inbred Plcg2Ali5/+
mice develop normally, but after birth gradually show spon-
taneous inflammation and autoimmunity, the severity of which
depends on age and gender [13]. For the current study, only
mice that did not yet show any obvious signs of inflammation
were used. Blood platelet counts, platelet size, and the
expression of prominent platelet surface receptors, including
aIIbb3, a2b1, GPIb, GPV, GPIX, CLEC-2, and GPVI, were
normal, demonstrating that the mutation had no effect on
platelet production (Table 1).
Increased ITAM-triggered IP3 production and Ca
2+
mobilization in Plcg2Ali5/+ platelets
To test the significance of the Ali5 mutation for PLC activity in
platelets, wemeasured IP3 production in response to the PLCb-
activating agonist thrombin and the GPVI/PLCc2-stimulating
agonist convulxin (CVX). For this, we quantified the stable IP3
metabolite IP1 by ELISA [20]. Whereas the increases in IP1
level in response to thrombin were comparable between wild-
type and Plcg2Ali5/+ platelets, the response to CVX was
markedly increased in the mutant cells as compared with
controls, indicating enhanced activity of the mutant PLCc2 in
platelets (Fig. 1A). Similar results were obtained when GPVI
was stimulated with CRP (data not shown).
The increased ITAM-triggered IP3 production resulted in
markedly enhanced Ca2+ mobilization from intracellular
stores in Plcg2Ali5/+ platelets upon CVX or CRP stimulation
as assessed by measuring changes in intracellular Ca2+
concentration in the absence of extracellular Ca2+. In contrast,
thrombin-induced Ca2+ mobilization was indistinguishable
between wild-type and mutant platelets (Fig. 1B,C). The
increased GPVI-induced Ca2+ mobilization in Plcg2Ali5/+
platelets also translated into markedly increased (store-oper-
ated) Ca2+ entry (Fig. 1B,C) in these cells, whereas overall
Ca2+ responses to thrombin were similar in wild-type and
mutant platelets. Thus, upon GPVI stimulation, Plcg2Ali5/+
platelets showed Ca2+ responses of similar amplitude to those
seen upon thrombin stimulation, whereas in wild-type platelets,
PLCc2 activation evoked much lower Ca2+ amplitudes.
Plcg2Ali5/+ platelets show enhanced responses upon GPVI and
CLEC-2 stimulation
To study the functional consequences of altered PLCc2 activity
in Plcg2Ali5/+ platelets, we performed standard aggregometry
with PRP or washed platelets, using different agonists. In
response to thrombin, ADP, or the stable TxA2 analog
U46619, Plcg2Ali5/+ platelets aggregated normally at all tested
concentrations (Fig. 2A), although a slightly faster reversion of
ADP-induced aggregation was consistently observed with
mutant platelets as compared with wild-type controls. In
contrast, when the cells were stimulated with collagen, CRP
(Fig. 2B), or CVX (not shown), a clearly enhanced response
was seen in mutant platelets that was most evident at low
agonist concentrations. At threshold concentrations of collagen
or CRP that did not induce aggregation of wild-type platelets,
Plcg2Ali5/+ platelets responded with irreversible aggregation.
At high collagen or CRP concentrations, aggregation of wild-
type and Plcg2Ali5/+ platelets was not significantly different.
Additionally, similarly increased reactivity was seen when
Table 1 Platelet count, size and glycoprotein (GP) expression in control
and Plcg2Ali5/+ mice
Wild type Plcg2Ali5/+
Platelets (nL)1) 1076 ± 23.1 1170 ± 22.7
MPV (fl) 5.3 ± 0.2 5.5 ± 0.06
GPVI 66 ± 7.4 64 ± 4.4
CLEC-2 96 ± 7.0 103 ± 3.0
aIIbb3 553 ± 34 485 ± 54.9
GPIb 391 ± 22.6 408 ± 22.4
GPV 273 ± 12.6 282 ± 16
GPIX 452 ± 29.8 466 ± 43.7
a2 103 ± 6.0 107 ± 8.0
b1 132 ± 11.0 138 ± 8.6
CD9 1258 ± 86.6 1345 ± 145.2
Platelet counts per nanoliter and platelet size in femtoliters, shown as
mean platelet volume (MPV), were analyzed with an automated blood
analyzer (Sysmex; n = 6 mice per group). To determine platelet GP
expression in Plcg2Ali5/+ mice, diluted whole blood was stained with
fluorophore-labeled antibodies at saturating concentrations for 15 min
at room temperature, and fluorescence from gated events was mea-
sured by flow cytometry using a FACSCalibur (Becton Dickinson,
Heidelberg, Germany). Results are given as the mean fluorescence
intensity ± standard deviation for at least six mice per group.
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Plcg2Ali5/+ platelets were stimulated with the CLEC-2-activat-
ing snake venom toxin rhodocytin (Fig. 2C).
Flow cytometric analysis of degranulation-dependent P-
selectin exposure and aIIbb3 activation confirmed enhanced
activation of Plcg2Ali5/+ platelets in response to GPVI and
CLEC-2 stimulation that was most evident at low and
intermediate agonist concentrations, whereas G-protein-cou-
pled agonists induced comparable activation of control and
mutant platelets (Fig. 2D,E). The enhanced degranulation of
Plcg2Ali5/+ platelets was also confirmed by an increase in
agonist-induced release of ATP, which is stored in dense
granules (Fig. 2F). Together, these results demonstrate en-
hanced activation and aggregation ofPlcg2Ali5/+ platelets upon
GPVI and CLEC-2 stimulation, but unaltered responses to G-
protein-coupled agonists.
Enhanced integrin outside-in signaling in Plcg2Ali5/+ platelets
PLCc2 has been shown to be involved in outside-in signal
transduction of ligand-occupied aIIbb3 in platelets [21,22], but
it is not clear whether its activity is a limiting factor in this
process. To test this directly, washed control and Plcg2Ali5/+
platelets were allowed to spread on immobilized fibrinogen, a
process that is dependent on aIIbb3 outside-in signaling [22]. It
is known that mouse platelets, in contrast to human platelets,
do not fully spread on fibrinogen without exogenous stimu-
lation [23]. Therefore, in order to increase the efficiency of
adhesion and spreading, the cells were stimulated with
0.008 U mL–1 thrombin. Under these conditions, platelets of
both groups were able to spread fully, but a marked difference
in kinetics between control and Plcg2Ali5/+ platelets became
evident (Fig. 3A, Videos VS1 and VS2). After 1 min,
approximately 40% ± 2.3% of the mutant platelets were
fully spread, whereas the wild-type platelets only adhered to
the fibrinogen matrix or started to develop filopodia. After
5 min, the first fully spread wild-type platelets were observed
(30% ± 9%) whereas 70% ± 11% of the mutant platelets
were already fully spread. These data demonstrate that PLCc2
activity determines, to a great extent, the efficacy of aIIbb3-
dependent platelet spreading.
Next, we tested the ability of the mutant platelets to spread
on a fibrinogen matrix in the absence of exogenous agonists.
Under these conditions, wild-type platelets attached to the
matrix but were unable to fully spread, whereas 67% ± 3%of
the Plcg2Ali5/+ platelets fully spread within 60 min (Fig. 3B,
Videos VS3 and VS4). Accelerated spreading of Plcg2Ali5/+
platelets was also observed when collagen (Fig. 3C) or laminin
(Fig. S2) matrices were used.
To further investigate the functional consequences of the
PLCc2 mutation for aIIbb3-dependent processes, we studied
clot retraction [24]. PRP of control and Plcg2Ali5/+ mice was
stimulated with 5 U mL–1 thrombin, and allowed to clot, and
subsequent clot retraction was monitored for 5 h. Consistent
with the results of the spreading assay, clot retraction was
significantly accelerated in Plcg2Ali5/+ platelets, with partial














































































Fig. 1. Increased phospholipase C (PLC) c2 activation and Ca2+ mobilization in Plcg2Ali5/+ platelets upon immunoreceptor tyrosine-based activation
motif (ITAM) stimulation. (A) Quantification of inositol 1-phosphate (IP1) produced upon platelet activation. Washed platelets were stimulated with the
indicated agonists for 5 min at 37 C. Platelets were lysed in the presence of LiCl, and IP1, a specific metabolite of inositol 1,4,5-trisphosphate, was
quantified using an enzyme-linked immunosorbent assay. Results are given as the mean IP1 concentration (nM) ± standard deviation (SD) (n = 3 per
group). (B) Time course of intracellular Ca2+ mobilization in wild-type (WT) platelets (black) and Plcg2Ali5/+ platelets (gray curve) in response to
thrombin (Thr) and collagen-related peptide (CRP). The experiments were performed in the absence and presence of extracellular Ca2+. The results shown
are representative of six individual experiments. (C) Maximal increase in cytosolic Ca2+ concentrations of wild-type platelets (black bars) and Plcg2Ali5/+
platelets (gray bars) after activation with the indicated agonists (thrombin, 0.1 U mL)1; CRP, 5 lg mL)1). Results are given as mean [Ca2+]i (nM) ± SD
(n ‡ 6 mice each); **P < 0.01. CVX, convulxin.
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respectively, whereas the process was completed only after 240–
300 min in wild-type platelets (Fig. 3C, left). At the end of the
observation period of 300 min, both wild-type and Plcg2Ali5/+
platelets showed complete clot retraction, and the amount of
remaining fluid determined at that time point was indistin-
guishable between the two groups (Fig. 3D). Together, these
results demonstrate that PLCc2 activity is a major determinant
of integrin outside-in signaling in platelets.
Virtually unlimited thrombus growth of Plcg2Ali5/+ platelets
on collagen under flow
To investigate the functional consequences of increased PLCc2
activity under more physiologic conditions, we analyzed
platelet adhesion and thrombus formation on collagen under
flow in a whole blood perfusion system [25]. Platelets were
fluorescently labeled, and the blood was perfused over a
collagen-coated surface at different wall shear rates (150, 1000
and 1700 s)1). Wild-type and Plcg2Ali5/+ platelets adhered to
collagen fibers, and the formation of platelet aggregates was
initiated within 2 min. However, whereas aggregates grew
slowly in wild-type blood, fast and virtually unlimited throm-
bus growth was seen in Plcg2Ali5/+ blood at all tested shear
rates. As a result, aggregates of Plcg2Ali5/+ platelets displayed
an altered shape and a dramatically increased total thrombus
volume as compared with the control at the end of the
perfusion period (Fig. 4A,B, Videos VS5 andVS6). In contrast,
the surface area covered by platelets was similar between the
two groups (Fig. 4C). These results demonstrate that PLCc2
activity determines, to a great extent, thrombus size under flow
conditions independently of the prevailing shear forces.
In collagen-adherent platelets, GPVI, a2b1 and aIIbb3 trigger
sustained Ca2+ responses leading to surface exposure of
procoagulant P-Selectin (PS), which is essential for local
thrombin production [25,26]. To test whether limited PLCc2
activity is also a regulator of this process, blood from wild-type
and Plcg2Ali5/+ mice was anticoagulated with PPACK and
heparin, and perfused over fibrillar collagen at a wall shear rate
of 1000 s)1. PS exposure on collagen-adherent platelets was
determined by annexin A5 staining. Whereas the surface area
covered by platelets at the end of the perfusion period was
similar between the two groups, the number of PS-exposing
platelets was markedly increased in Plcg2Ali/5+ blood as
compared with the control (Fig. 4D–E). Thus, increased
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Fig. 2. Increased platelet responses upon glycoprotein (GP) VI and CLEC-2 stimulation. (A–C) Platelets from wild-type (WT) mice (black line) and
Plcg2Ali5/+ mice (gray line) were activated with G-protein-coupled agonists (A), immunoreceptor tyrosine-based activation motif-coupled agonists (B), or
rhodocytin (Rc) (C). Light transmission was recorded on a Fibrintimer 4 channel aggregometer over 10 min, and is expressed as arbitrary units, with 100%
transmission adjusted with plasma. The results shown are representative of four individual experiments. (D, E)Washed blood fromwild-type andPlcg2Ali5/
+mice was incubated for 10 min with the indicated agonists in the presence of JON/A–phycoerythrin (PE) antibody directed against the activated form of
mouse integrin aIIbb3 (D) or a fluorescein isothiocyanate (FITC)-conjugated anti-mouse P-selectin antibody (E). The cells were gated by forward scatter/
side scatter characteristics. Data shown are mean fluorescence intensity (MFI) ± standard deviation (SD) (n = 6 per group). *P < 0.05; **P < 0.01;
***P < 0.001. (F) Measurement of released ATP. Washed platelets were incubated for 2 min at 37 C with the indicated agonists and fixed. Using a
luminometric assay ATP present in the supernatant was determined. Results are given as mean ATP concentration (lM) ± SD (n = 6 per group). CRP,
collagen-related peptide; NS, not significant; Thr, thombin.
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PLCc2 activity results in enhanced coagulant activity of
platelets.
Increased mortality of Plcg2Ali5/+ mice in a model of
pulmonary thromboembolism
To investigate the in vivo significance of the platelet hyper-
reactivity in Plcg2Ali5/+ mice, the animals were challenged in a
model of pulmonary thromboembolism triggered by intrave-
nous injection of collagen and epinephrine (0.15 mg kg)1;
60 lg kg)1 body weight) [27]. At these agonist doses, all
Plcg2Ali5/+ mice died within 30 min after injection, whereas
90% of the wild-type mice survived and recovered completely
(Fig. 5A). In line with this, the numbers of circulating platelets
2 min after the challenge were significantly lower in Plcg2Ali5/+
mice than in controls (Fig. 5B), whereas the number of
obstructed vessels in the lungs was significantly increased in
the mutant animals (Fig. 5C,D). These results demonstrate
that increased PLCc2 activity in platelets leads to largely
uncontrolled thrombotic responses in vivo.
Discussion
In this study, we have shown that the expression of a
hyperactive variant of PLCc2 in platelets leads to accelerated
signaling through the major platelet receptors GPVI, CLEC-2,
and aIIbb3. This dysregulation translated into virtually unlim-
ited thrombus formation on collagen under flow conditions
in vitro and a prothrombotic phenotype in vivo. Thus, a tight
limitation of PLCc2 activity, even in response to maximal
thrombogenic stimuli, appears to be essential for appropriate
platelet activation at sites of endothelial damage to ensure
sealing of the wound while avoiding vessel obstruction.
Despite the expression of mutant hyperactive PLCc2,
Plcg2Ali5/+ mice display normal platelet production and
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Fig. 3. Enhanced integrin outside-in signaling in Plcg2Ali5/+ platelets. (A) Washed platelets from the indicated mice were stimulated with 0.008 U mL)1
thrombin and allowed to adhere and spread on immobilized human fibrinogen (1 mg mL)1) for 20 min. Differential interference contrast (DIC) images
taken after 20 min, representative of five individual experiments, are shown. The number of adherent platelets, the degree of filopod formation and the
number of fully spread platelets were determined at different time points (1, 5, 10 and 20 min). Bar: 5 lm. (B) Platelet spreading and adhesion on
immobilized human fibrinogen without exogenous stimulus. Representative DIC images taken after 20, 40 and 60 min, respectively. The bar graph depicts
mean values ± standard deviation (SD) (n ‡ 5 mice per group); ***P < 0.001. Bar: 5 lm. (C) Platelet spreading and adhesion on soluble collagen.
Representative DIC images taken after 5, 20 and 40 min, respectively, are shown. The bar graph depicts mean values ± SD (n ‡ 5 mice per group). Bar:
5 lm. (D) Platelet-rich plasma was stimulated with 5 U mL)1 thrombin in the presence of 20 mM CaCl2 to induce clot retraction. Representative images
show the ongoing process at different time points (0, 60, 120 and 300 min). The remaining fluid was determined at the end of the experiment. The bar graph
depicts mean values ± SD (n = 3 mice per group). WT, wild type.
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confirmed by the observations that the platelet lifespan in the
mutant animals is indistinguishable from that in control
animals ( 5 days; data not shown) and that stimulation of
the cells with weak agonists such as epinephrine or serotonin
did not lead to enhanced activation as compared with the
control (not shown). This strongly suggests that hyperactive
PLCc2 has no influence on the basic enzymatic activity of the
enzyme. This is also supported by largely unaltered tyrosine
phosphorylation of the mutant enzyme as compared with the
control before and upon platelet activation, although a
tendency for slightly faster dephosphorylation was observed
120 s after stimulation (Fig. S1).
A critical role of PLCc2 in platelet activation in vitro and
in vivo has been demonstrated in previous studies showing
defective GPVI-mediated activation in vitro [28,29] and
impaired thrombus formation at sites of superficial vascular
damage in a model of laser-induced injury in mice lacking the
enzyme [30]. In the latter study, Nonne et al. demonstrated
that thrombus formation partially involves PLCc2 activation,
depending on the severity of the vascular lesion. At sites of
deep laser injury, PLCc2 deficiency can be functionally
compensated for by thrombin/Gq/PLCb-dependent activa-
tion, leading to the formation of large, stable thrombi. These
results demonstrate that strong Gq/PLCb stimulation is
sufficient to induce powerful thrombotic activity of platelets
that can lead to vessel occlusion. Remarkably, however, lack
of PLCc2 leads to impaired primary hemostasis, suggesting
that PLCc2-dependent signaling in platelets is important for
sealing of a wound, although this defect can be partially
compensated by PLCb, as revealed by moderately increased
bleeding times inPlcg2)/)mice as comparedwithb3-deficient or
GPIba-deficient mice [28]. Taken together, these findings
indicate that PLCc2 is an important mediator of thrombus
growth and stability in primary hemostasis and arterial throm-
bosis inmice, but also that PLCb-dependent signalingpathways
can partially compensate for its loss in these processes.
Stimulation of PLCb or PLCc2 results in different kinetics
and amplitudes of Ca2+ mobilization in platelets. Under
maximal agonist stimulation, PLCb induces an intracellular
Ca2+ increase with a high amplitude but fast reversion,
whereas PLCc2 mediates submaximal but sustained Ca2+
mobilization. We found that signaling of the hyperactive
PLCc2 induced a strong increase in intracellular Ca2+
concentrations that was comparable to that elicited by
thrombin stimulation. As a consequence, Plcg2Ali5/+ platelets







































































Fig. 4. Gain-of-function mutation of phospholipase C (PLC) c2 induces elevated thrombus formation on collagen under flow.Whole blood was perfused
over a collagen-coated (0.2 mg mL)1) surface at the indicated shear rates, and then washed with Tyrodes buffer for the same perfusion time. (A)
Representative phase-contrast and fluorescent images at a shear rate of 1000 s)1. Bar: 100 lm. The profile intensity is shown for wild-type (WT) and
Plcg2Ali5/+ thrombi. (B) Relative thrombus volume as measured by the integrated fluorescent intensity of fluorescently labeled platelets per visual field. (C)
Mean thrombus surface coverage. All bar graphs depict mean values ± standard deviation (SD) (n ‡ 5 mice per group). ***P < 0.001. (D) Determi-
nation of phosphatidylserine exposure as ameasure of procoagulant activity of platelets by OG488–annexin A5 staining. Fluorescent images and statistical
analysis (E) of annexin A5 fluorescence.
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in vitro that translated into a prothrombotic phenotype in vivo.
This was also confirmed by a marked increase in PS exposure
upon interaction with collagen that, under physiologic condi-
tions, leads to increased local generation of thrombin at the
platelet surface [31]. This indicates that the enzymatic activity
of PLCc2 needs to be precisely regulated to allow efficient but
limited platelet activation at sites of vascular injury.
Our data suggest that PLCb and PLCc isoforms are
differentially regulated to control either fast and reversible or
sustained adhesion-dependent processes in platelet activation
and aggregation. Such differential regulation of distinct cellular
processes is also found in other cell types. PLCc has been
demonstrated to be crucial for pre-BCR and BCR-dependent
selection events duringB-cell differentiation [32], but appears to
be also critical for T-cell and natural killer cell function [33]. In
these cell types, PLCc leads to sustained signals with long
ligand exposure times that allow prolonged activation in
response to ligand binding. Whereas PLCc2 deficiency leads to
a block in B-cell differentiation as well as a loss of T-cell-
independent antibody production and inhibited IgM receptor-
induced Ca2+ flux [34], hyperactive PLCc2 specifically
increases extracellular Ca2+ entry into B cells, which is
comparable to the increased Ca2+ mobilization in platelets
observed in this study (Fig. 1), and leads to expansion of innate
inflammatory cells, identifying PLCc2 as a key regulator in
immune responses [13]. In contrast, PLCb becomes activated
downstream of receptors that trigger fast but reversible
responses, such as chemokine receptors [35], suggesting that
different kinetics of these PLCs might also be responsible for
appropriate responses in immune cells.
Thrombus formation is a multiple step process that involves
signaling through two major activatory receptors that stim-
ulate PLCc2, namely GPVI and CLEC-2. GPVI is of central
importance for platelet activation on subendothelial collagens
[36], whereas it may not have a major direct function in
subsequent thrombus growth. In contrast, a very recent study
on mice with a transient antibody-induced CLEC-2 deficiency
revealed that CLEC-2 is crucial for the activation of newly
recruited platelets in a growing thrombus but is not required
for adhesion to the damaged vessel wall [12]. As a conse-
quence, CLEC-2-deficient mice displayed severely impaired
thrombus formation in vitro and protection from arterial
thrombosis in vivo [12]. Locally produced thrombin was not
sufficient to achieve stable thrombus formation in those mice,
demonstrating that CLEC-2 signaling is essential for this
process to occur in vivo. On the basis of these data, we speculate
that, as well as GPVI and aIIbb3, increased CLEC-2-dependent
signalingcontributes to thevirtuallyunlimited thrombusgrowth
of Plcg2Ali5/+ platelets under flow. This suggests that tight
regulation of CLEC-2 and PLCc2 activity is required to avoid
excessive thrombus growth and vessel occlusion.
Our studies confirm that PLCc2 is involved in aIIbb3
outside-in signaling [22], and reveal that its activity is a
limiting step in this process. Mutant platelets spread signifi-
cantly faster on a fibrinogen matrix under stimulating
conditions. Remarkably, hyperreactive PLCc2 was sufficient
to induce full spreading of murine platelets under non-
stimulating conditions. In previous studies, McCarty et al.
demonstrated that stimulation of murine platelets with





















































Fig. 5. Collagen-induced pulmonary thromboembolism model. Lethal pulmonary thromboembolism after injection of collagen and epinephrine in
anesthetized wild-type (WT) and Plcg2Ali5/+ mice. (A) Mortality rate upon injection of 150 lg of collagen per kg of body weight. Animals alive 30 min
after the challenge were considered to be survivors. (B) Platelet counts in control and Plcg2Ali5/+ mice 2 min after infusion of collagen/epinephrine. (C, D)
Representative pictures of hematoxylin and eosin-stained lung sections; thrombi per visual field were counted at · 20 magnification. Mean ± standard
deviation for 50 fields per group is shown. Bar: 200 lm.
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lamellipodia formation, whereas human platelets bind and
fully spread on immobilized fibrinogen in the absence of
external agonists [23], like Plcg2Ali5/+ platelets. This indicates
that a difference in the degree of integrin-dependent PLCc2
activation may exist between human and murine platelets.
Furthermore, PLCc2 is not essential for aIIbb3-mediated clot
retraction, most likely because this process is regulated by
different molecules, for example PLCb, Rho kinase, and
PLCc1 [21]. However, this process was also enhanced in the
mutant mice, demonstrating that PLCc2 activity is also a rate-
limiting factor in this process.
Taken together, our findings show that PLCc2 activity is a
major determinant of appropriate platelet activation to ensure
efficient but limited thrombus formation. This indicates that
modulation of PLCc2 activity in platelets might be a promising
approach for antithrombotic therapy. Indeed, mice lacking the
PLCc2-coactivating small GTPase Rac1 are protected from
arterial thrombosis [20]. Similarly, GPVI deficiency caused by
antibody treatment also protects mice from arterial thrombosis
[36] and ischemic brain infarction [37], while only moderately
affecting hemostasis.
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